# Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

> **NCT04996264** · PHASE2 · COMPLETED · sponsor: **Ophirex, Inc.** · enrollment: 95 (actual)

## Conditions studied

- Snakebites
- Envenoming
- Envenoming, Snake
- Envenomation, Snake

## Interventions

- **DRUG:** Varespladib Methyl
- **DRUG:** Placebo
- **DRUG:** Standard of care (SOC)

## Key facts

- **NCT ID:** NCT04996264
- **Lead sponsor:** Ophirex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-15
- **Primary completion:** 2023-06-07
- **Final completion:** 2023-06-08
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996264, "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04996264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*